SJEPD030367_D1.RNA-Seq
EPN · Anaplastic EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Anaplastic EPN
- cancer_type
- EPN
- subtype
- Anaplastic EPN
- age_years
- 5.78
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -1.775318773
- umap2_2d
- 1.317704073
- umap1_3d
- -0.13094325
- umap2_3d
- 3.791989701
- umap3_3d
- -3.302585973
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.650
- E2F_TARGETS+0.600
- MYC_TARGETS_V2+0.600
- G2M_CHECKPOINT+0.530
- UNFOLDED_PROTEIN_RESPONSE+0.510
- OXIDATIVE_PHOSPHORYLATION+0.490
- MTORC1_SIGNALING+0.450
- PROTEIN_SECRETION+0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.380
- DNA_REPAIR+0.370
Top 10 suppressed
- APICAL_SURFACE-0.420
- MYOGENESIS-0.370
- KRAS_SIGNALING_DN-0.360
- APICAL_JUNCTION-0.250
- IL6_JAK_STAT3_SIGNALING-0.250
- ESTROGEN_RESPONSE_EARLY-0.160
- XENOBIOTIC_METABOLISM-0.160
- COAGULATION-0.140
- WNT_BETA_CATENIN_SIGNALING-0.140
- BILE_ACID_METABOLISM-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 5F350242-0CF6-43AC-AB06-2C130D85C5CC | — | — | 0.891 |
| 2 | 1FB9316D-4674-4D97-A33B-649F53D09487 | — | — | 0.887 |
| 3 | A07BA2E1-CCA0-4231-A391-B13383A2BCB9 | — | — | 0.884 |
| 4 | E0DE33EA-C3DF-478E-9C4D-86E3C7B3A1D9 | — | — | 0.879 |
| 5 | TCGA-05-4415-01A-22R-1858-07 | — | cohortA4 | 0.873 |
| 6 | SJEPD030168_D1.RNA-Seq | EPN | EPN Tumor | 0.872 |
| 7 | AA605CB6-ABD9-4802-8784-75A18A74C87B | — | — | 0.868 |
| 8 | SRR12475103 | — | — | 0.867 |
| 9 | 8F828A42-3E60-40C1-9E7D-428ABEA6C72F | — | — | 0.865 |
| 10 | SRR8518311 | — | E | 0.857 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.650 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.510 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.490 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.450 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.380 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.370 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.290 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.120 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.110 | Inavolisib | — uncovered |